Results 61 to 70 of about 314,952 (197)

Treatment of Recurrent Thymoma

Chinese Journal of Lung Cancer, 2020
Thymoma is a potential malignant disease with a recurrence rate of 10% to 30% after complete resection. There is no agreement on the treatment strategy and standard for recurrent thymoma.
Xianping LIU, Xiao LI, Jianfeng LI
doaj   +1 more source

Epidemiology of thymoma [PDF]

Journal of Thoracic Disease, 2020
Thymic tumours are a heterogeneous group of malignancies with a range of clinical presentations. The most common types are thymoma and thymic carcinoma, but overall it remains a rare cancer, and one without a clear aetiology. In this review of the epidemiology of the disease, the relationship between sex, age, and ethnicity is reviewed, along with ...
openaire   +2 more sources

Thymoma and autoimmunity [PDF]

Cellular & Molecular Immunology, 2011
The thymus is a central lymphatic organ that is responsible for many immunological functions, including the production of mature, functional T cells and the induction of self-tolerance. Benign or malignant tumors may originate from the thymus gland, with thymoma being the most common and accounting for 50% of anterior mediastinal tumors.
Shahar, Shelly, Nancy, Agmon-Levin, Arie, Altman, Yehuda, Shoenfeld   +3 more
openaire   +2 more sources

Urinary Dysfunction in Myasthenic Syndromes: A Scoping Review of Clinical Features and Treatment‐Related Associations

Muscle &Nerve, EarlyView.
ABSTRACT Urinary dysfunction has been reported in association with myasthenic syndromes, including myasthenia gravis (MG), Lambert–Eaton myasthenic syndrome (LEMS), and congenital myasthenic syndromes (CMS), but evidence regarding its prevalence, clinical impact, pathophysiology, and management remains limited.
Julia M. Augustin, Lillith Horstkorte, Hellen Schmidt, Blanca G. Sánchez Navarro, Avan Kader, Inga Koneczny, Holly M. Nelson, Pratishtha P. Wadnerkar, Rafael Meleka Hanna, Ayşe N. Özdağ Acarlı, Piraye Oflazer, Atay Vural, Franz Blaes, Miriam L. Fichtner   +13 more
wiley   +1 more source

Identification of Potential Key Genes for the Comorbidity of Myasthenia Gravis With Thymoma by Integrated Bioinformatics Analysis and Machine Learning

Bioinformatics and Biology Insights
Background: Thymoma is a key risk factor for myasthenia gravis (MG). The purpose of our study was to investigate the potential key genes responsible for MG patients with thymoma.
Hui Liu, Geyu Liu, Rongjing Guo, Shuang Li, Ting Chang   +4 more
doaj   +1 more source

Sclerosing Thymoma

Archives of Pathology & Laboratory Medicine, 2015
Sclerosing thymoma is an extremely rare entity described mostly in the recent past and, to our knowledge, described in only 14 cases, including one we recently diagnosed at our institution. The pathogenesis and biologic behavior of this relatively unknown entity is still largely uncertain.
Deyali, Chatterjee, Christie Jean, Finch
openaire   +2 more sources

Exploring the Value of Quantitative Muscle Ultrasound in Neuromuscular Junction Disorders: A Pilot Study

Muscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims Quantitative muscle ultrasound (QMUS) is a validated technique for assessing muscle pathology, yet its role in disorders primarily affecting the neuromuscular junction (NMJ) remains unclear. This pilot study aimed to explore whether QMUS is associated with structural muscle changes in patients with acquired or genetic NMJ ...
Artor Pogosean, Maarika Liik, Nens van Alfen, Anna Rostedt Punga   +3 more
wiley   +1 more source

Management of Refractory Thymoma‐Associated Myasthenia Gravis With Sequential FcRn Antagonist and Complement Inhibition Combined With Resection of Pleural Dissemination

Neurology and Clinical Neuroscience, EarlyView.
ABSTRACT Myasthenia gravis (MG) associated with disseminated thymoma is often refractory to conventional treatments due to continuous autoantibody production. The optimal treatment strategy, particularly the combination of complement component 5 (C5) inhibitor, neonatal Fc receptor (FcRn) antagonist, and surgical resection in thymoma‐associated ...
Hiroyuki Takenaka, Madoka Iida, Yuki Fukami, Masahisa Katsuno   +3 more
wiley   +1 more source

Peripheral Blood Lymphocytosis Reflecting an Underlying Thymoma

American Journal of Hematology, EarlyView.
Léa Ousset, Alban Canali, Barbara J. Bain   +2 more
wiley   +1 more source

A Review of the Australian MRI Linac Program: From Pie in the Sky to Research Milestone

Journal of Medical Imaging and Radiation Oncology, EarlyView.
ABSTRACT The Australian Magnetic Resonance Imaging (MRI) Linear Accelerator program (MRI linac) was a major research project that aimed to build and test a unique MRI linac prototype for cancer treatment. It aimed to improve radiotherapy anatomical targeting and explore physiological targeting. The purpose of this report is to summarise the development
Michael Bernard Barton, Geoffrey Paul Delaney, Peter Greer, Lois Holloway, Peter Metcalfe, Robba Rai, Trang Pham, William S. Price, David Waddington, Stuart Crozier, Paul Keall   +10 more
wiley   +1 more source